BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 18257513)

  • 1. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.
    Manetti F; Brullo C; Magnani M; Mosci F; Chelli B; Crespan E; Schenone S; Naldini A; Bruno O; Trincavelli ML; Maga G; Carraro F; Martini C; Bondavalli F; Botta M
    J Med Chem; 2008 Mar; 51(5):1252-9. PubMed ID: 18257513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
    Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
    Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study.
    Radi M; Dreassi E; Brullo C; Crespan E; Tintori C; Bernardo V; Valoti M; Zamperini C; Daigl H; Musumeci F; Carraro F; Naldini A; Filippi I; Maga G; Schenone S; Botta M
    J Med Chem; 2011 Apr; 54(8):2610-26. PubMed ID: 21443205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.
    Carraro F; Naldini A; Pucci A; Locatelli GA; Maga G; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Modugno M; Tintori C; Manetti F; Botta M
    J Med Chem; 2006 Mar; 49(5):1549-61. PubMed ID: 16509573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells.
    Manetti F; Pucci A; Magnani M; Locatelli GA; Brullo C; Naldini A; Schenone S; Maga G; Carraro F; Botta M
    ChemMedChem; 2007 Mar; 2(3):343-53. PubMed ID: 17295370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
    Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
    Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells.
    Carraro F; Pucci A; Naldini A; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Manetti F; Botta M
    J Med Chem; 2004 Mar; 47(7):1595-8. PubMed ID: 15027847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
    ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
    Dreassi E; Zizzari AT; Mori M; Filippi I; Belfiore A; Naldini A; Carraro F; Santucci A; Schenone S; Botta M
    Eur J Med Chem; 2010 Dec; 45(12):5958-64. PubMed ID: 20970221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and anti-tumor activities of novel pyrazolo[1,5-a]pyrimidines.
    Li J; Zhao YF; Zhao XL; Yuan XY; Gong P
    Arch Pharm (Weinheim); 2006 Nov; 339(11):593-7. PubMed ID: 17036367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
    Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
    J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
    Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
    J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and antiproliferative activity in vitro of new 2-, 3- or 4-substituted pyrido[2',3':3,4]pyrazolo[1, 5-a]pyrimidines.
    Poreba K; Wietrzyk J; Opolski A
    Acta Pol Pharm; 2006; 63(3):189-94. PubMed ID: 20085223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
    Antonini I; Polucci P; Magnano A; Sparapani S; Martelli S
    J Med Chem; 2004 Oct; 47(21):5244-50. PubMed ID: 15456268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
    Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
    J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line.
    Schenone S; Bruno O; Bondavalli F; Ranise A; Mosti L; Menozzi G; Fossa P; Donnini S; Santoro A; Ziche M; Manetti F; Botta M
    Eur J Med Chem; 2004 Nov; 39(11):939-46. PubMed ID: 15501543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.
    Taliani S; La Motta C; Mugnaini L; Simorini F; Salerno S; Marini AM; Da Settimo F; Cosconati S; Cosimelli B; Greco G; Limongelli V; Marinelli L; Novellino E; Ciampi O; Daniele S; Trincavelli ML; Martini C
    J Med Chem; 2010 May; 53(10):3954-63. PubMed ID: 20408530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line.
    Jung MH; Kim H; Choi WK; El-Gamal MI; Park JH; Yoo KH; Sim TB; Lee SH; Baek D; Hah JM; Cho JH; Oh CH
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6538-43. PubMed ID: 19857963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel 6-N-arylcarboxamidopyrazolo[4,3-d]pyrimidin-7-one derivatives as potential anti-cancer agents.
    Devegowda VN; Kim JH; Han KC; Yang EG; Choo H; Pae AN; Nam G; Choi KI
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1630-3. PubMed ID: 20138760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.